Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2014

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #556

    http://abstracts.asco.org/144/AbstView_144_127438.html

    1 Reply Last reply
    0
    • investor1989I Offline
      investor1989I Offline
      investor1989
      wrote on sidst redigeret af
      #557

      Sanofis kombo data med Revlimid er ikke mega stærke: The ORR (≥ PR), according to IMWG criteria, among 12 evaluable pts was 58 %. Responses occurred at each DL of 3mg/kg (1PR), 5mg/kg (1PR, 1 VGPR) and 10 mg/kg (1PR, 3 VGPR).

      1 Reply Last reply
      0
      • investor1989I Offline
        investor1989I Offline
        investor1989
        wrote on sidst redigeret af
        #558

        pt. ingen CR !!!!!!!

        1 Reply Last reply
        0
        • investor1989I Offline
          investor1989I Offline
          investor1989
          wrote on sidst redigeret af
          #559

          DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM. Encouraging early activity is seen with marked reduction in M-protein and 8/11 patients (72%) achieving PR or better. Part 2 data will be presented

          1 Reply Last reply
          0
          • investor1989I Offline
            investor1989I Offline
            investor1989
            wrote on sidst redigeret af
            #560

            SAR overall response rate er ikke mega god. http://abstracts.asco.org/144/AbstView_144_129808.html kun 33% ORR i patienter behandlet med over 10 mg. de har dog 11% CR i de patienter. men stadigvæk.. Dara har noget højere ORR dog lavere CR

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #561

              http://abstracts.asco.org/144/AbstView_144_133856.html SAR ... Ja ikke skræmmende i konkurrencen

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #562

                OMFG tjek lige Ibrutinib+Arzerra kombi data. de er outstanding: Overall response rate in CLL/SLL was 100%

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #563

                  Arzerra er markant undervurderet af analytikerne

                  1 Reply Last reply
                  0
                  • investor1989I Offline
                    investor1989I Offline
                    investor1989
                    wrote on sidst redigeret af
                    #564

                    http://abstracts.asco.org/144/AbstView_144_132436.html At study end, 52/58 responders (90%) remained progression-free with f/u of 16, 12 and 11 months for G1, 2 and 3, respectively

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #565

                      det er i fuckin 72 patienter de leverer så høj en ORR

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #566

                        Data fra part 2 data i dara+revlimid til ASCO. De bliver interessante.

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #567

                          .. Og bemærk 2 pts har kun fået en behandling

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JSEH
                            wrote on sidst redigeret af
                            #568

                            Fatter ikke hat. Men i bander så det må være ok 😉

                            1 Reply Last reply
                            0
                            • investor1989I Offline
                              investor1989I Offline
                              investor1989
                              wrote on sidst redigeret af
                              #569

                              det aller bedste er for mig at se at det ikke ser ud til at SAR er Dara overlegen.

                              1 Reply Last reply
                              0
                              • investor1989I Offline
                                investor1989I Offline
                                investor1989
                                wrote on sidst redigeret af
                                #570

                                pt. vil jeg kalde dem equal

                                1 Reply Last reply
                                0
                                • investor1989I Offline
                                  investor1989I Offline
                                  investor1989
                                  wrote on sidst redigeret af
                                  #571

                                  deres follow up data viser kun 33% ORR i monoterapi. Daras viser 48%. De har så 11% CR hvor Dara ikke laver nogen

                                  1 Reply Last reply
                                  0
                                  • investor1989I Offline
                                    investor1989I Offline
                                    investor1989
                                    wrote on sidst redigeret af
                                    #572

                                    i kombination med revlimid ser de også meget ens ud mht. effekt. osv. så first mover fordelen for Dara er virkelig en fordel

                                    1 Reply Last reply
                                    0
                                    • investor1989I Offline
                                      investor1989I Offline
                                      investor1989
                                      wrote on sidst redigeret af
                                      #573

                                      og vildt med arzerra+ibrutinib kombi dataene. De må da tage det i phase III !!!!!!!!!

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        poxon2
                                        wrote on sidst redigeret af
                                        #574

                                        Jeg fatter heller ikke meget af det her.. men hvad er jer der er klogere på området vurdering - oversat til dansk: skal vi op eller ned?

                                        1 Reply Last reply
                                        0
                                        • investor1989I Offline
                                          investor1989I Offline
                                          investor1989
                                          wrote on sidst redigeret af
                                          #575

                                          jeg vil sige op pga. det giver mig en forløsning at dara ser ud til at være på niveau med SAR

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger